Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

Last updated: July 19, 2023
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
Overall Status: Completed

Phase

N/A

Condition

Cancer/tumors

Rectal Cancer

Carcinoma

Treatment

Measurement of platelet count at diagnosis

Clinical Study ID

NCT03717519
CHIR CR
  • Ages 18-100
  • All Genders

Study Summary

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients.

In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Colorectal cancer with synchronous liver metastases
  • Possibility to retrieve pre-operative platelet count
  • Age of 18 years or older
  • Availabilty of clinical-pathological data
  • Minimum follow up of 12 months

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 196
Treatment Group(s): 1
Primary Treatment: Measurement of platelet count at diagnosis
Phase:
Study Start date:
January 01, 2018
Estimated Completion Date:
September 01, 2018

Connect with a study center

  • Chirurgia Generale ed Epatobiliare, Policlinico GB Rossi

    Verona, 37134
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.